Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amnestic Mild Cognitive Impairment
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
Trial Timeline
Nov 5, 2013 → Apr 17, 2018
NCT ID
NCT01953601About Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2) is a phase 3 stage product being developed by Merck for Amnestic Mild Cognitive Impairment. The current trial status is terminated. This product is registered under clinical trial identifier NCT01953601. Target conditions include Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease.
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01953601 | Phase 3 | Terminated |
Competing Products
1 competing product in Amnestic Mild Cognitive Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK-8931 | Merck | Phase 1 | 29 |